These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30339243)

  • 1. Clearing the air: towards agreement about access to high cost cancer medicines.
    Lipworth W; Kerridge I; Ghinea N; Zalcberg J
    Ann Oncol; 2019 Jan; 30(1):143-146. PubMed ID: 30339243
    [No Abstract]   [Full Text] [Related]  

  • 2. Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.
    Ghinea N; Little M; Lipworth W
    J Bioeth Inq; 2017 Sep; 14(3):401-410. PubMed ID: 28721607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging the soaring price of cancer medicines: a call for equity and transparency.
    Gonçalves A; Maraninchi D; Vernant JP
    Ann Oncol; 2016 Sep; 27(9):1812-3. PubMed ID: 27154419
    [No Abstract]   [Full Text] [Related]  

  • 4. Value-based payment models in oncology: will they help or hinder patient access to new treatments?
    Shah S; Reh G
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP188-SP190. PubMed ID: 28665677
    [No Abstract]   [Full Text] [Related]  

  • 5. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 6. Health Equity.
    Carlos RC; Flores EJ
    J Am Coll Radiol; 2019 Apr; 16(4 Pt B):539-541. PubMed ID: 30947884
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    Eide AH; Braathen SH
    Tidsskr Nor Laegeforen; 2017 Nov; 137(21):. PubMed ID: 29135178
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 9. [What is the fair price of innovative therapy?].
    Fischer A; Dewatripont M; Goldman M
    Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 11. THE MOST FAVORED NATIONS MODEL INTERIM FINAL RULE IS FATALLY FLAWED AND MUST BE RESCINDED-YET THE PROBLEM IT ADDRESSES DEMANDS A SOLUTION.
    Rubinstein E
    J Manag Care Spec Pharm; 2021 Feb; 27(2):286. PubMed ID: 33506733
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved access to the innovative anticancer therapies in resource-limited countries: call for global action.
    Vaez-Gharamaleki Y; Hosseini MS
    Int J Surg; 2024 Jul; 110(7):4477-4478. PubMed ID: 38537083
    [No Abstract]   [Full Text] [Related]  

  • 13. Funding breakthrough therapies: A systematic review and recommendation.
    Hanna E; Toumi M; Dussart C; Borissov B; Dabbous O; Badora K; Auquier P
    Health Policy; 2018 Mar; 122(3):217-229. PubMed ID: 29223847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we afford innovation?
    Morgenstern L
    Surg Innov; 2007 Jun; 14(2):138-9. PubMed ID: 17558021
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.
    Sruamsiri R; Wagner AK; Ross-Degnan D; Lu CY; Dhippayom T; Ngorsuraches S; Chaiyakunapruk N
    BMJ Open; 2016 Mar; 6(3):e008671. PubMed ID: 26988346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 17. When drugs are worth more than gold!
    Schwartsmann G; Picon PD
    Lancet Oncol; 2007 Dec; 8(12):1049-1050. PubMed ID: 18054873
    [No Abstract]   [Full Text] [Related]  

  • 18. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reimbursement of new medical therapy].
    Ehlers AP; Wenke A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):849-55. PubMed ID: 21698539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.